You know Doc, most of the shorts on this board, don't really dislike ARWR. Most had a terrible childhood, or were made fun of at school or playgrounds when small, or had parent issues. This is their chance to get back at those that made fun of them , when they were young. They sit here ever day and make fun of something, most don't know anything about,but its part of settling a score. Most professional shorts, know what they are doing, and don't need to be bad mouthing the Science when there are people dying from HBV everyday. JMO.
Gee, ALNY, GILD come to mind. Is that what your meant???? Waiter, a order of burnt toast.
Conclusion - Integration of therapeutic strategies to better control HBV infection. Current efforts to develop innovative strategies to better control HBV are divided into three interdependent arms that complement and synergize each other: Interference with viral life cycle and spread, immune modulation and directly targeting cccDNA. The elimination of cccDNA is the ultimate goal in future therapy and is a perquisite for viral eradication and cure.
From GGZ on twitter
@cfcstar @BioBoyScout Yes, they are going after FC in e-. If successful, $ARWR will be a $10B company to say the least.
Sure glad you're here, and posting what might be wrong w/the company. I think I will sell and wait for awhile...on 2nd thought, I think now, I will just put you in IGNORE. Now that is better. This guy doesn't know #$%$ from shinola. Note - Meaning. Possessing poor judgment or knowledge 2nd Note - He has a agenda...
TypArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company’s second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. This study may have multiple readouts, including single dose safety data, single dose antiviral activity data, and multiple dose safety and antiviral activity data. e message
4mins ago from BoyScout.
@BioBoyScout really no reason to be pursuing HDV this early unless you're seeing great success in treating HBV. $ARWR showing their cards.
Just posted on Twitter - Of course, Shorts, Analysts, and Dirk won't agree, but someday the "Chickens will come home to roost." It's only a matter of TIME.